VioQuest Pharmaceuticals, Inc. (OTC BB: VOQP)

VioQuest Pharmaceuticals, Inc. (OTC BB: VOQP) , a New Jersey-based biotechnology company, is focused on becoming a leader in the successful development of novel drug therapies designed to target both the molecular basis of cancer and side effects of treatment. The company’s oncology portfolio currently includes: Xyfid™, for the treatment of dry skin conditions and to manage the burning and itching associated with various dermatoses; VQD-002, a targeted inhibitor of Akt activation; and Lenocta™, an inhibitor of certain protein tyrosine phosphatases. For further information, visit the Company’s web site at www.vioquestpharm.com.